Literature DB >> 34377095

Commonly Prescribed and Over-the-Counter Drugs as Secondary Causes of Osteoporosis-Part Two.

Joseph Pizzorno, Lara Pizzorno.   

Abstract

In this second of a 2-part editorial, we continue our discussion of the importance of being aware that some clinically important prescription drugs can impair bone metabolism. While obviously most critical for women (and men) with osteopenia or osteoporosis, the guidance here is directly relevant to all patients as many are already experiencing decreased bone regeneration even if not severe enough for a formal diagnosis. Part One covered aromatase inhibitors, gonadotropin-releasing hormone agonists, anticonvulsants, benzodiazepines, antidepressants, insulin sensitizers, and NSAIDs and acetaminophen. Part Two covers opioids, glucocorticoids, calcineurin inhibitors, gastric acid blockers, diuretics, anti-coagulants, thyroid hormone medications, and contraceptives.
Copyright © 2021 InnoVision Professional Media Inc.

Entities:  

Year:  2021        PMID: 34377095      PMCID: PMC8325506     

Source DB:  PubMed          Journal:  Integr Med (Encinitas)        ISSN: 1546-993X


  61 in total

1.  Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration.

Authors:  John Simes; Cecilia Becattini; Giancarlo Agnelli; John W Eikelboom; Adrienne C Kirby; Rebecca Mister; Paolo Prandoni; Timothy A Brighton
Journal:  Circulation       Date:  2014-08-25       Impact factor: 29.690

2.  Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.

Authors:  Douglas A Corley; Ai Kubo; Wei Zhao; Charles Quesenberry
Journal:  Gastroenterology       Date:  2010-03-27       Impact factor: 22.682

Review 3.  Progesterone and bone: a closer link than previously realized.

Authors:  V Seifert-Klauss; M Schmidmayr; E Hobmaier; T Wimmer
Journal:  Climacteric       Date:  2012-04       Impact factor: 3.005

4.  Oral contraceptive use and bone mineral density in premenopausal women: cross-sectional, population-based data from the Canadian Multicentre Osteoporosis Study.

Authors:  J C Prior; S A Kirkland; L Joseph; N Kreiger; T M Murray; D A Hanley; J D Adachi; Y M Vigna; C Berger; L Blondeau; S A Jackson; A Tenenhouse
Journal:  CMAJ       Date:  2001-10-16       Impact factor: 8.262

5.  Time trends in osteoporosis risk factor profiles: a comparative analysis of risk factors, comorbidities, and medications over twelve years.

Authors:  Jakob Præst Holm; Lars Hyldstrup; Jens-Erik Beck Jensen
Journal:  Endocrine       Date:  2016-05-13       Impact factor: 3.633

6.  Characterisation and potential diagnostic value of circulating matrix Gla protein (MGP) species.

Authors:  Ellen C M Cranenburg; Ralf Koos; Leon J Schurgers; Elke J Magdeleyns; Thea H M Schoonbrood; Robert B Landewé; Vincent M Brandenburg; Otto Bekers; Cees Vermeer
Journal:  Thromb Haemost       Date:  2010-08-05       Impact factor: 5.249

Review 7.  Resolution of Acute Inflammation and the Role of Resolvins in Immunity, Thrombosis, and Vascular Biology.

Authors:  Brian E Sansbury; Matthew Spite
Journal:  Circ Res       Date:  2016-06-24       Impact factor: 17.367

Review 8.  Bone density recovery after depot medroxyprogesterone acetate injectable contraception use.

Authors:  Andrew M Kaunitz; Raquel Arias; Michael McClung
Journal:  Contraception       Date:  2008-02       Impact factor: 3.375

9.  Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.

Authors:  Yan Meng; Hao Zhang; Yingbin Li; Qingnan Li; Li Zuo
Journal:  Bone       Date:  2013-10-18       Impact factor: 4.398

10.  Antihypertensive Medications, Loop Diuretics, and Risk of Hip Fracture in the Elderly: A Population-Based Cohort Study of 81,617 Italian Patients Newly Treated Between 2005 and 2009.

Authors:  Giovanni Corrao; Paolo Mazzola; Matteo Monzio Compagnoni; Federico Rea; Luca Merlino; Giorgio Annoni; Giuseppe Mancia
Journal:  Drugs Aging       Date:  2015-11       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.